리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 12월
페이지 정보:영문 504 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 ISH(In Situ Hybridization) 시장은 2030년까지 15억 달러에 이를 전망
2024년에 10억 달러로 추정되는 세계의 ISH(In Situ Hybridization) 시장은 2024-2030년의 분석 기간에 CAGR 6.6%로 성장하여 2030년까지 15억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석 대상으로 한 부문 중 하나인 FISH는 6.5%의 CAGR을 보이고, 분석 기간 종료까지 11억 달러에 이를 것으로 예측됩니다. CISH 부문의 성장률은 분석 기간에 7.1%의 CAGR을 보일 전망입니다.
미국 시장은 4억 2,630만 달러로 추정되어 중국은 8.1%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다
미국의 ISH(In Situ Hybridization) 시장은 2024년에 4억 2,630만 달러로 추정되고 있습니다. 세계 제2위 경제 규모를 자랑하는 중국은 2024-2030년의 분석 기간에 CAGR 8.1%로 성장을 지속하여, 2030년까지 1억 740만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역 시장으로서는 일본과 캐나다를 들 수 있으며, 각각 분석 기간 중에 5.7%, 6.5%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 유럽에서는 독일이 약 6.7%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.
세계의 ISH(In Situ Hybridization) 시장-주요 시장 동향과 촉진요인 요약
ISH(in situ hybridization)는 고정된 조직이나 세포 내에서 특정 핵산 서열을 검출하고 국소화하기 위해 사용되는 강력한 분자 기술입니다. 이 방법에서는 표지된 상보적 DNA 또는 RNA 프로브를 시료 내 표적 서열에 하이브리다이제이션하는 방식입니다. 프로브는 일반적으로 형광 또는 발색성 표지가 부착되어 있어 현미경으로 하이브리드화된 서열을 시각화할 수 있습니다. ISH는 유전자 발현, 염색체 구조, 핵산의 공간적 분포를 조사하기 위해 연구 및 임상 진단에 널리 활용되고 있습니다. 유전적 이상 확인, 바이러스 감염 감지, 다양한 질병의 기저에 있는 분자 메커니즘을 규명하는 데 매우 유용하다는 것이 입증되었습니다.
기술 발전으로 원위 하이브리드화의 민감도, 특이성, 범용성이 크게 향상되었습니다. 형광 원위 하이브리드화(FISH)의 개발로 서로 다른 색상의 형광 프로브를 사용하여 여러 표적을 동시에 검출할 수 있게 되어 보다 상세하고 종합적인 분석이 가능해졌습니다. 자동화 ISH 플랫폼의 도입으로 처리 능력과 재현성이 향상되어 일상적인 임상 적용이 더욱 쉬워졌습니다. 또한, 고정 핵산(LNA) 프로브 및 분지 DNA(bDNA) 증폭과 같은 새로운 프로브 설계 전략의 도입으로 저발현 표적의 검출 능력이 향상되고 있습니다. 이러한 혁신으로 ISH의 적용 범위가 확대되어 종양학, 바이러스학, 발생생물학 등 다양한 분야에서 활용이 촉진되고 있습니다.
원위 하이브리드화 시장의 성장은 몇 가지 요인에 의해 촉진되고 있습니다. 암과 유전성 질환의 유병률 증가는 중요한 촉진요인이며, ISH는 이러한 질환의 정확한 진단과 맞춤 치료 계획 수립에 필수적인 도구입니다. ISH는 프로브 설계 및 검출 방법의 기술적 진보를 통해 더 높은 민감도와 특이성을 달성하여 조사 환경과 임상 환경 모두에서 채택을 촉진하고 있습니다. 상세한 분자 프로파일링에 의존하는 정밀의료에 대한 수요 증가도 시장을 견인하고 있으며, ISH는 유전자 발현 패턴과 유전자 변이에 대한 귀중한 통찰력을 제공합니다. 또한, 생명공학 및 제약 산업의 확장은 고급 진단 및 연구 도구의 필요성을 높이고 있으며, 이는 ISH 시장의 성장을 뒷받침하고 있습니다. 또한, 분자진단과 맞춤형 의료를 촉진하기 위한 정부 자금과 시책이 ISH 기술의 활용을 더욱 촉진하고 있습니다. 이러한 요인들이 결합하여 원위 하이브리드화 시장은 역동적으로 확대되고 있으며, 분자진단 및 연구 분야에서 혁신과 발전의 큰 기회를 제공합니다.
부문:
기술별(FISH, CISH), 용도별(암 진단, 면역학, 신경과학, 세포학, 감염증 진단), 최종사용자별(병원 및 진단실험실, 제약 기업 및 바이오테크놀러지 기업, 수탁 연구기관, 학술기관 및 연구기관)
조사 대상 기업 예
Abbott Laboratories, Inc.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
BioGenex
Abnova Corporation
Bio-Techne Corporation
Biocare Medical LLC
Leica Biosystems Nussloch GmbH
Advanced Cell Diagnostics, Inc.
Empire Genomics LLC
Biodot, Inc.
IMRIS, Deerfield Imaging, Inc.
Creative Biolabs
Bio Sb
Guangzhou Ruibo Biotechnology Co., Ltd.
AI 통합
검증된 전문가 컨텐츠와 AI 툴을 통해 시장 및 경쟁 정보 분석 방식을 혁신하고 있습니다.
Market Glass, Inc.는 LLM이나 산업 특화형 SLM을 쿼리하는 일반적인 방식이 아닌, 전 세계 도메인 전문가들이 엄선한 컨텐츠 리포지토리를 구축했습니다. 여기에는 비디오 전사, 블로그, 검색엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등이 포함됩니다.
관세 영향 계수
Market Glass, Inc.가 본사 소재지, 생산기지, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁 변화를 예측하면서 지리적 시장에 대한 관세의 영향을 반영하였습니다. 이러한 복잡하고 다면적인 시장 현실은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 경쟁사들에게 다양한 영향을 미칠 것입니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트(UAE)
기타 중동
아프리카
제4장 경쟁
LSH
영문 목차
영문목차
Global In Situ Hybridization (ISH) Market to Reach US$1.5 Billion by 2030
The global market for In Situ Hybridization (ISH) estimated at US$1.0 Billion in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2024-2030. Fluorescence In Situ Hybridization (FISH), one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Chromogenic In Situ Hybridization (CISH) segment is estimated at 7.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$426.3 Million While China is Forecast to Grow at 8.1% CAGR
The In Situ Hybridization (ISH) market in the U.S. is estimated at US$426.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$107.4 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.7% and 6.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.7% CAGR.
Global In situ Hybridization Market - Key Trends & Drivers Summarized
In situ hybridization (ISH) is a powerful molecular technique used to detect and localize specific nucleic acid sequences within fixed tissues and cells. This method involves the hybridization of a labeled complementary DNA or RNA probe to the target sequence within the sample. The probes are typically tagged with fluorescent or chromogenic labels, allowing for the visualization of the hybridized sequences under a microscope. ISH is widely used in research and clinical diagnostics to study gene expression, chromosome structure, and the spatial distribution of nucleic acids. It has proven invaluable in identifying genetic abnormalities, detecting viral infections, and investigating the molecular mechanisms underlying various diseases.
Technological advancements have significantly enhanced the sensitivity, specificity, and versatility of in situ hybridization. The development of fluorescent in situ hybridization (FISH) has enabled the simultaneous detection of multiple targets using differently colored fluorescent probes, allowing for more detailed and comprehensive analyses. Automated ISH platforms have improved throughput and reproducibility, making the technique more accessible for routine clinical use. Additionally, the introduction of novel probe design strategies, such as locked nucleic acid (LNA) probes and branched DNA (bDNA) amplification, has increased the detection capability of low-abundance targets. These innovations have expanded the application range of ISH, facilitating its use in various fields including oncology, virology, and developmental biology.
The growth in the in situ hybridization market is driven by several factors. The increasing prevalence of cancer and genetic disorders is a significant driver, as ISH is a critical tool for accurate diagnosis and personalized treatment planning in these conditions. Technological advancements in probe design and detection methods are making ISH more sensitive and specific, encouraging its adoption in both research and clinical settings. The rising demand for precision medicine, which relies on detailed molecular profiling, is also boosting the market, as ISH provides valuable insights into gene expression patterns and genetic alterations. Furthermore, the expansion of the biotechnology and pharmaceutical industries is driving the need for advanced diagnostic and research tools, supporting the growth of the ISH market. Additionally, government funding and initiatives aimed at advancing molecular diagnostics and personalized medicine are further promoting the use of ISH technologies. Together, these factors are fostering a dynamic and expanding market for in situ hybridization, presenting significant opportunities for innovation and development in molecular diagnostics and research.
SCOPE OF STUDY:
The report analyzes the In Situ Hybridization (ISH) market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Technique (Fluorescence In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH)); Application (Cancer Diagnostics, Immunology, Neuroscience, Cytology, Infectious Disease Diagnostics); End-Use (Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations, Academic & Research Institutions)
Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.
Select Competitors (Total 38 Featured) -
Abbott Laboratories, Inc.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
BioGenex
Abnova Corporation
Bio-Techne Corporation
Biocare Medical LLC
Leica Biosystems Nussloch GmbH
Advanced Cell Diagnostics, Inc.
Empire Genomics LLC
Biodot, Inc.
IMRIS, Deerfield Imaging, Inc.
Creative Biolabs
Bio Sb
Guangzhou Ruibo Biotechnology Co., Ltd.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
In Situ Hybridization (ISH) - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
Global Economic Update
In Situ Hybridization: A Prelude
Future Prospects Remain Favorable for Insitu Hybridization
Chromogenic ISH: Gaining Over FISH
FISH Technology Continues to Find Favor
How is FISH Better than Conventional Techniques?
Probe Types and Application
Fluorescent In Situ Hybridization Emerges as Cytological Tool of Choice for Plethora of Scientific Applications
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Cancer Drives the Demand for In-situ Hybridization
Diverse Applications of FISH Technology in Oncology
Growing Demand for Targeted Therapies in Cancer Treatment Presents Lucrative Opportunities
Growing Number of Genetic Disorders and Emphasis on Genetic Testing Bodes Well for the Growth of ISH Market
List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
Top Ten Genetic Diseases Worldwide
Rise in Prenatal Testing Drives Opportunities
FISH in Detection of Prenatal Genetic Abnormalities
In Situ Hybridization Advances Present Perfect Tools to Detect Genetic Anomalies
Uptrend in Companion Diagnostics Market Augurs Well
World Companion Diagnostics Market (in US$ Million) for the Years 2019, 2021, 2023 & 2025
Companion Diagnostics Lead the Way to Personalized Medicine
Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
State-Sponsored Molecular Research Initiatives Bode Well for Market Growth
Increasing Research on Application of ISH in infectious Disease Diagnostics to Drive Growth
Infectious Diseases Related Mortality High Among Children Below 5 Years: Breakdown of Leading Causes of Death in Children Below 5 Years (in %) Cause % Share
Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
FISH in Detection of Microbiological Pathogens
Growth in In-vitro Diagnostics (IVD) for Diagnosis of Chronic Diseases Promise Opportunities
High Demand for IVD Devices Promises Opportunities for FISH Probes: Global IVD Instruments Market (In US$ Billion) for the Years 2018, 2020, 2022, 2024 & 2027
Rising R&D Investments in the Biotech Sector Drives Gains
Emergence of Automated Diagnostic Kits
Novel Approach of Highly-Multiplexed FISH for In-Situ Genomics
Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Fluorescence In Situ Hybridization (FISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 2: World Historic Review for Fluorescence In Situ Hybridization (FISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 3: World 15-Year Perspective for Fluorescence In Situ Hybridization (FISH) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Chromogenic In Situ Hybridization (CISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 5: World Historic Review for Chromogenic In Situ Hybridization (CISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 6: World 15-Year Perspective for Chromogenic In Situ Hybridization (CISH) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 8: World Historic Review for Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 9: World 15-Year Perspective for Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 11: World Historic Review for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 12: World 15-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Neuroscience by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 14: World Historic Review for Neuroscience by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 15: World 15-Year Perspective for Neuroscience by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Cytology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 17: World Historic Review for Cytology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 18: World 15-Year Perspective for Cytology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 20: World Historic Review for Infectious Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 21: World 15-Year Perspective for Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 23: World Historic Review for Hospitals & Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 24: World 15-Year Perspective for Hospitals & Diagnostic Labs by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 25: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 26: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 27: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 28: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 29: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 30: World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 31: World Recent Past, Current & Future Analysis for Academic & Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 32: World Historic Review for Academic & Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 33: World 15-Year Perspective for Academic & Research Institutions by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
Automation Equipment Benefit the In-Situ Hybridization Market
TABLE 34: World In Situ Hybridization (ISH) Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
TABLE 35: World Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for In Situ Hybridization (ISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 37: World 15-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 38: USA Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 39: USA Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 40: USA 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 42: USA Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 43: USA 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: USA Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 46: USA 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
CANADA
TABLE 47: Canada Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 48: Canada Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 49: Canada 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: Canada Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 52: Canada 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 53: Canada Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: Canada Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 55: Canada 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
JAPAN
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 56: Japan Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: Japan Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 58: Japan 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 59: Japan Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 60: Japan Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 61: Japan 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 62: Japan Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: Japan Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 64: Japan 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
CHINA
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 65: China Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: China Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 67: China 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: China Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 70: China 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 71: China Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: China Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 73: China 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
EUROPE
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 74: Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: Europe Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 76: Europe 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: Europe Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 79: Europe 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: Europe Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 82: Europe 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 84: Europe Historic Review for In Situ Hybridization (ISH) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 85: Europe 15-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
FRANCE
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 86: France Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: France Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 88: France 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 89: France Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: France Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 91: France 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 92: France Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: France Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 94: France 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
GERMANY
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 95: Germany Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 96: Germany Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 97: Germany 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 98: Germany Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: Germany Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 100: Germany 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 101: Germany Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: Germany Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 103: Germany 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
ITALY
TABLE 104: Italy Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: Italy Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 106: Italy 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 107: Italy Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Italy Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 109: Italy 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 110: Italy Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: Italy Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 112: Italy 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
UNITED KINGDOM
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 113: UK Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: UK Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 115: UK 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 116: UK Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: UK Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 118: UK 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 119: UK Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 120: UK Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 121: UK 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
SPAIN
TABLE 122: Spain Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: Spain Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 124: Spain 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 125: Spain Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 126: Spain Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 127: Spain 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 128: Spain Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: Spain Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 130: Spain 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
RUSSIA
TABLE 131: Russia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 132: Russia Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 133: Russia 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 134: Russia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 135: Russia Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 136: Russia 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 137: Russia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 138: Russia Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 139: Russia 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: Rest of Europe Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 142: Rest of Europe 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 144: Rest of Europe Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 145: Rest of Europe 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 147: Rest of Europe Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 148: Rest of Europe 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
ASIA-PACIFIC
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 151: Asia-Pacific 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: Asia-Pacific Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 154: Asia-Pacific 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 156: Asia-Pacific Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 157: Asia-Pacific 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 159: Asia-Pacific Historic Review for In Situ Hybridization (ISH) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 160: Asia-Pacific 15-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
AUSTRALIA
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 161: Australia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 162: Australia Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 163: Australia 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 164: Australia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 165: Australia Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 166: Australia 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 167: Australia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 168: Australia Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 169: Australia 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
INDIA
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 170: India Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 171: India Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 172: India 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 173: India Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 174: India Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 175: India 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 176: India Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 177: India Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 178: India 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 179: South Korea Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 180: South Korea Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 181: South Korea 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 182: South Korea Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 183: South Korea Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 184: South Korea 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 185: South Korea Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 186: South Korea Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 187: South Korea 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 189: Rest of Asia-Pacific Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 190: Rest of Asia-Pacific 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 192: Rest of Asia-Pacific Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 193: Rest of Asia-Pacific 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 195: Rest of Asia-Pacific Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 196: Rest of Asia-Pacific 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
LATIN AMERICA
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 197: Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 199: Latin America 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 200: Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 201: Latin America Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 202: Latin America 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 203: Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 204: Latin America Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 205: Latin America 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
TABLE 206: Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 207: Latin America Historic Review for In Situ Hybridization (ISH) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 208: Latin America 15-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Revenues for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
ARGENTINA
TABLE 209: Argentina Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 210: Argentina Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 211: Argentina 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 212: Argentina Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 213: Argentina Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 214: Argentina 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 215: Argentina Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 216: Argentina Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 217: Argentina 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
BRAZIL
TABLE 218: Brazil Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 219: Brazil Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 220: Brazil 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 221: Brazil Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 222: Brazil Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 223: Brazil 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 224: Brazil Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 225: Brazil Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 226: Brazil 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
MEXICO
TABLE 227: Mexico Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 228: Mexico Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 229: Mexico 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 230: Mexico Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 231: Mexico Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 232: Mexico 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 233: Mexico Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 234: Mexico Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 235: Mexico 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 237: Rest of Latin America Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 238: Rest of Latin America 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 240: Rest of Latin America Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 241: Rest of Latin America 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 243: Rest of Latin America Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 244: Rest of Latin America 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
MIDDLE EAST
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 245: Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 247: Middle East 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 248: Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 249: Middle East Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 250: Middle East 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 251: Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 252: Middle East Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 253: Middle East 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
TABLE 254: Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 255: Middle East Historic Review for In Situ Hybridization (ISH) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 256: Middle East 15-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Revenues for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
IRAN
TABLE 257: Iran Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 258: Iran Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 259: Iran 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 260: Iran Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 261: Iran Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 262: Iran 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 263: Iran Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 264: Iran Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 265: Iran 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
ISRAEL
TABLE 266: Israel Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 267: Israel Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 268: Israel 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 269: Israel Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 270: Israel Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 271: Israel 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 272: Israel Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 273: Israel Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 274: Israel 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 276: Saudi Arabia Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 277: Saudi Arabia 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 279: Saudi Arabia Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 280: Saudi Arabia 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 282: Saudi Arabia Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 283: Saudi Arabia 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 284: UAE Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 285: UAE Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 286: UAE 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 287: UAE Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 288: UAE Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 289: UAE 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 290: UAE Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 291: UAE Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 292: UAE 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 294: Rest of Middle East Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 295: Rest of Middle East 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 297: Rest of Middle East Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 298: Rest of Middle East 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 300: Rest of Middle East Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 301: Rest of Middle East 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030
AFRICA
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 302: Africa Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 303: Africa Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 304: Africa 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2015, 2025 & 2030
TABLE 305: Africa Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 306: Africa Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 307: Africa 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2015, 2025 & 2030
TABLE 308: Africa Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 309: Africa Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 310: Africa 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2015, 2025 & 2030